MAT

Bicycle Health and Evernorth Team Up to Expand Access to Virtual Opioid Use Disorder Treatment

Retrieved on: 
Thursday, August 25, 2022
Office of Inspector General, U.S. Department of Health and Human Services, OIG, CEO, Program, Opioid use disorder, MAT, Conditional sentence, GLOBE, Leadership, News, OUD, HHS, History of the Office of the Inspector General of the United States Army, Patient, Buprenorphine/naloxone, Â, Health insurance, Cigna

Bicycle Healths virtual care model dramatically increases access to OUD treatment which is largely inaccessible in an in-person setting.

Key Points: 
  • Bicycle Healths virtual care model dramatically increases access to OUD treatment which is largely inaccessible in an in-person setting.
  • ( source )
    Through Bicycle Health, customers will have access to behavioral health clinicians who can help develop a personalized care plan, including a prescription to Buprenorphine/Naloxone (Suboxone), if appropriate.
  • Opioid use disorder is highly stigmatized in the US, which directly contributes to 90 percent of people with the disorder not pursuing treatment, said Ankit Gupta, CEO and founder of Bicycle Health.
  • Bicycle Health offers confidential evidence-based virtual care for opioid use disorder , from the comfort of your home.

Fentanyl Drives Fatal Overdoses to Over 107,000 Annually in the U.S. - Healthcare Providers' Effort to Fight Back

Retrieved on: 
Wednesday, August 24, 2022
Fentanyl, Homelessness, Research, Opioid use disorder, Drug, MAT, Risk assessment, Society, Sexual abuse, ASAM, Shame, Health, Asthma, Pain management, Prescription, Oregon Health Authority, Quality of life, Organization, Center, Transitive dependency, GLOBE, Patient, Hypertension, Substance use disorder, SUD, Stigma, Pharmacy, Korea Disease Control and Prevention Agency, Addiction medicine, Oregon Health Plan, McWilliams, Risk, Diabetes, American Society of Addiction Medicine, Naloxone, CDC, Pharmaceutical industry, Risk management, Equinox

American Society of Addiction Medicine (ASAM) encourages the co-prescribing of naloxone for people at risk of overdose , including those diagnosed with and being treated for opioid use disorder.

Key Points: 
  • American Society of Addiction Medicine (ASAM) encourages the co-prescribing of naloxone for people at risk of overdose , including those diagnosed with and being treated for opioid use disorder.
  • "If they say yes, 95% of them will say someone has given them naloxone."
  • Often, the drugs being consumed are a mixture of a variety of illicit substances, including fentanyl.
  • "Unfortunately, in the past there has been the misconception that naloxone was a medication that enabled drug abuse.

Empire BlueCross BlueShield Announces Four New Partnerships to Address Behavioral Healthcare Needs in New York

Retrieved on: 
Tuesday, August 23, 2022
Other Consumer, Women, Other Health, Teens, Men, Children, Telemedicine, Virtual Medicine, Insurance, Mental Health, Family, Consumer, Professional Services, Practice Management, LGBTQ+, Managed Care, General Health, Health, Health Insurance, Clifford Whittingham Beers, Partnership, Blue Cross Blue Shield Association, Medicaid, CEO, Opioid use disorder, Addiction medicine, ERP, Commercial, MAT, MBE, Insurance, Blue Shield, LinkedIn, Psychiatry, MD, Credentialing, Response, OCD, Twitter, Language, Tic disorder, OUD, Geography, Empire HealthChoice Assurance, Inc. v. McVeigh, Patient, Region, Hospital, Health insurance, Medicine, Pharmaceutical industry, Health, Headway, New Yorkers, Medicare

Today, Empire BlueCross BlueShield (Empire) is announcing a suite of innovative companies that are joining the Empire provider network as the company works to respond to the growing needs for behavioral healthcare services in New York.

Key Points: 
  • Today, Empire BlueCross BlueShield (Empire) is announcing a suite of innovative companies that are joining the Empire provider network as the company works to respond to the growing needs for behavioral healthcare services in New York.
  • Were excited to be entering a partnership with Empire BlueCross BlueShield to increase access to diverse, equitable, and affordable mental healthcare for New Yorkers, said Harry Ritter, founder and CEO, Alma.
  • Since launching with Empire in June 2022, more than 5,300 Empire members have received mental healthcare through Headway, with the average time to care just 5.9 days.
  • Serving New Yorkers for more than 85 years, Empire BlueCross BlueShield (Empire) is on a mission to materially and measurably improve the health of New Yorkers.

Greenhouse Treatment Center Designated as a Blue Distinction® Center for Substance Use Treatment and Recovery

Retrieved on: 
Monday, August 22, 2022
Patient safety, Research, CEO, Program, Accreditation, Knee, MAT, Blue, Substance, Addiction, Center, GLOBE, BDC, Opioid, Korea Disease Control and Prevention Agency, Transplant, Bariatric surgery, Greenhouse, Patient, Hospital, Residential care

GRAND PRAIRIE, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- To help patients suffering from a substance use disorder find facilities that deliver quality treatment and care, BCBSTX recognizes Greenhouse Treatment Center as one of the first facilities to receive the Blue Distinction Center for Substance Use Treatment and Recovery (BDC Substance Use Treatment and Recovery) designation a new designation under the Blue Distinction Specialty Care program.

Key Points: 
  • GRAND PRAIRIE, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- To help patients suffering from a substance use disorder find facilities that deliver quality treatment and care, BCBSTX recognizes Greenhouse Treatment Center as one of the first facilities to receive the Blue Distinction Center for Substance Use Treatment and Recovery (BDC Substance Use Treatment and Recovery) designation a new designation under the Blue Distinction Specialty Care program.
  • The BDC Substance Use Treatment and Recovery program requires designated facilities to deliver coordinated multidisciplinary care to patients and provide timely access to quality medical and psychosocial care in all phases of treatment.
  • Designated facilities must also offer medication-assisted treatment (MAT) a way to treat opioid addiction that includes a medication component and behavioral therapy.
  • Being one of the first addiction treatment facilities to receive such a prestigious designation is an immense honor, said Tyler Harrell, CEO of Greenhouse Treatment Center.

Ophelia Appoints Lon Binder as Chief Technology Officer to Increase Investment in Technology

Retrieved on: 
Monday, August 22, 2022
Medicaid, Health equity, CEO, Technology, Opioid use disorder, Addiction medicine, Commercial, MAT, Chief technology officer, Heart, Culture, Warby Parker, Centers for Medicare & Medicaid Services, Organization, Creativity, NEW, Psychiatry, FDA, Internet, Optometry, Knowledge, OUD, CTO, Growth, Patient, Pharmaceutical industry, Medicare, City block

NEW YORK, Aug. 22, 2022 /PRNewswire/ -- Ophelia, digital provider of medication-assisted treatment (MAT) for opioid use disorder (OUD), today announced the expansion of both its executive team and technological capabilities with the appointment of Chief Technology Officer (CTO), Lon Binder. Former CTO of Cityblock Health, Binder brings a wealth of knowledge and in-depth experience in health equity and technology to Ophelia, to enhance both the patient and clinical experiences that Ophelia provides.

Key Points: 
  • Former CTO of Cityblock Health, Binder brings a wealth of knowledge and in-depth experience in health equity and technology to Ophelia, to enhance both the patient and clinical experiences that Ophelia provides.
  • As CTO, Binder will also manage a team of product designers and engineers who will support this work and further technological growth for Ophelia.
  • "Lon is an experienced technology leader with a rare combination of vision, creativity, heart, and drive."
  • Binder brings robust experience across technology and health equity spaces to his new role at Ophelia.

Bicycle Health and Tele911 Partner to Bring OUD Care to Emergency Patients

Retrieved on: 
Tuesday, August 16, 2022
CEO, GLOBE, Addiction, Telehealth, Substance abuse, MAT, EMS, Patient, SAN, OUD, Opioid, Partnership, ERS, Medication, Opioid use disorder, Organization, Health insurance

A Tele911 Licensed Social Worker will refer the patient to Bicycle Health for continued support and care.

Key Points: 
  • A Tele911 Licensed Social Worker will refer the patient to Bicycle Health for continued support and care.
  • Onboarding patients in emergency situations through the partnership with Tele911 will ensure that even the most vulnerable populations can discover and access Bicycle Health, helping to close the treatment gap when they need it most.
  • Compared to traditional in-person care, Bicycle Healths model yields increased retention numbers, meaning 86% of insured patients are still in treatment after 30 days.
  • About Bicycle Health: Bicycle Heath is a remote-first digital health start-up that offers online Medication for Addiction Treatment (MAT) for individuals with Opioid Use Disorder.

BioCorRx Provides Business Update for the Second Quarter of 2022

Retrieved on: 
Tuesday, August 16, 2022
FDA, U.S. Securities and Exchange Commission, AUD, NIH, Curriculum, GLOBE, Naltrexone, CFO, CEO, Addiction, CA, CBT, Orange County, National Institute, IND, National, Security (finance), Substance abuse, Clinical trial, Nutritionist, MAT, Cognitive behavioral therapy, RFA, Company, OUD, Program, National Institute on Drug Abuse, NIDA, Safety, Drug development, Post-traumatic stress disorder, Research, OTCQB, Veteran, Solution, NCT, PTSD, Volunteering, Annual report, Opioid use disorder, Pharmacokinetics, Investigational New Drug, Pharmaceutical industry, Drug overdose

ANAHEIM, CA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire BioCorRx Inc. (OTCQB: BICX) (the Company), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and reported on recent corporate developments.

Key Points: 
  • ANAHEIM, CA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire BioCorRx Inc. (OTCQB: BICX) (the Company), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and reported on recent corporate developments.
  • We are pleased to report that this month we have enrolled and dosed several more subjects.
  • We believe this program will offer veterans suffering with substance abuse and other related disorders an enhanced treatment solution.
  • A copy of the Companys annual report on Form 10-Q for the second quarter ended June 30, 2022 has been filed with the Securities and Exchange Commission and posted on the Companys website at https://ir.biocorrx.com/ .

SIGGRAPH 2022 Hybrid Conference Enjoys Notable Numbers with In-Person and Virtual Attendees

Retrieved on: 
Friday, August 12, 2022
Metaverse, Computer graphics, Exhibition, Technology, DNEG, Memorial Sloan Kettering Cancer Center, MAT, Lists of publishing companies, Pixar, Purdue University, Bird, SIGGRAPH, Lists of academic journals, Walt Disney Animation Studios, UCSB, University, Conference, University of California, AR, Advanced Technology Program, Video game, Film, VR

Access to the virtual component of SIGGRAPH 2022 will continue through 31 October 2022.

Key Points: 
  • Access to the virtual component of SIGGRAPH 2022 will continue through 31 October 2022.
  • SIGGRAPH 2022 offered a platform to share exceptional offerings in digital art, technology, computer science, and various innovations from more than 2,400 contributors.
  • The conference and virtual experience were enjoyed by an international audience from 74 countries and garnered 30,000-plus views during the livestream sessions across the four-day, in-person conference.
  • "Every year we gather our global community to showcase how computer graphics and interactive techniques shape the future," said Munkhtsetseg Nandigjav, SIGGRAPH 2022 Conference Chair.

Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022

Retrieved on: 
Monday, August 8, 2022
FDA, World Health Organization, Hematology, NDA, PAP, GLOBE, Treosulfan, Customer service, Growth, Investment, Methotrexate, TSX, Pharmacy, Research, MAT, IQVIA, Rheumatoid arthritis, Blood, Allergy, Marketing, Patient, Review, Calendar, Mission statement, Glioma, Health Canada, Hematopoietic stem cell transplantation, CDH, Webcast, Time, SEDAR, Video game, Pharmaceutical industry, Renewable energy, Aquaculture, Rupal State, Collaboration

TORONTO and CHICAGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s first fiscal quarter ended June 30, 2022. All dollar amounts in this press release are in United States dollars unless specified otherwise.

Key Points: 
  • Delivered record total revenue of $23.0 million in fiscalQ12023, an increase of 33% compared to $17.3million in fiscalQ12022 and an increase of 13% compared to $20.3million in fiscalQ42022.
  • Achieved Adjusted EBITDA* of $1.9million in fiscalQ12023 compared to $(4.9)million in fiscalQ12022 and $1.1 million in fiscal Q4 2022.
  • Medexus achieved this Adjusted EBITDA increase while continuing to maintain appropriate investments in preparations for a commercial launch of treosulfan in the United States.
  • In addition, in August 2022, Medexus and medac signed an amendment to their February 2021 license agreement for treosulfan.

Adore Me Releases Inaugural ESG Report and Provides Blueprint for Sustainability Transformation

Retrieved on: 
Thursday, July 28, 2022
Goal, Professional corporation, Adore Me, Water, Industry, DTC, Woman, CEO, MAT, Outline, AIM, Marketing, PBC, National Voluntary Guidelines on Social, Environmental and Economic Responsibilities of Business, Exercise, GAME, ESG, Budget, Element, Risk management

NEW YORK, July 28, 2022 /PRNewswire/ -- Adore Me, known for being the first lingerie brand to bring extended sizing to the market, today published its first ESG (environmental social and governance) report, highlighting how the brand is integrating sustainability into every element of its business and taking a compliance-first approach to critical ESG initiatives. The full report can be found here. 

Key Points: 
  • In this ESG report, Adore Me has outlined goals for 2022, 2023, 2025, 2030, and 2050covering all sectors of its business, including product design, raw materials, manufacturing, transport, warehouse logistics, and retail.
  • In establishing these goals, Adore Me pledges to further their sustainability efforts and to hold every stakeholder at the organization accountable to these standards.
  • This report was prepared using the GRI Sustainability Reporting Standards, used by 10,000 companies worldwide, as a reference.
  • As an innovation-driven team, Adore Me is revolutionizing affordable sustainability through cutting-edge technologies and advanced innovations at affordable price points.